Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc. is experiencing strong sales momentum for its ophthalmic product, Lytenava, with unit sales reportedly doubling in the UK and Germany in 1Q26 compared to the previous quarter, indicating robust market demand. The company plans to expand its presence in key EU markets such as France, Italy, and Spain in 2027, which could further enhance revenue growth prospects. Despite a narrowed operating loss and ongoing FDA approval anticipation for ONS-5010, the current market price is seen as significantly undervalued, suggesting considerable upside potential for shareholders.

Bears say

Outlook Therapeutics Inc has experienced a significant decline in research and development (R&D) expenses, dropping 62.4% year-over-year to $3.6 million, which raises concerns about the company's ability to sustain its development pipeline. General and administrative (G&A) expenses also fell by 27.9% to $8.6 million, yet they still exceeded expectations, indicating a potential misalignment in cost management. Furthermore, the declining market for ophthalmic treatments, including an approximately 12-month price drop in the US ranibizumab market, suggests challenges for the commercialization of ONS-5010, while the company’s reliance on a single development program heightens the risk of negative outcomes from both market dynamics and clinical trials.

OTLK has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 3 analysts, OTLK has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.